Cargando…

Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study

AIMS/INTRODUCTION: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long‐term treatments are available. METHODS: This was an investigator‐initiated multicenter prospective intervention study in which ipragliflozin (50 mg) was administered once daily, and g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsuba, Ikuro, Kawata, Takehiro, Iemitsu, Kotaro, Asakura, Taro, Amemiya, Hikaru, Ishikawa, Masashi, Ito, Syogo, Kaneshiro, Mizuki, Kanamori, Akira, Kubota, Akira, Shinoda, Kazuaki, Takai, Masahiko, Takuma, Tetsuo, Takihata, Masahiro, Takeda, Hiroshi, Tanaka, Keiji, Matsuzawa, Yoko, Machimura, Hideo, Minagawa, Fuyuki, Minami, Nobuaki, Mokubo, Atsuko, Miyakawa, Masaaki, Terauchi, Yasuo, Tanaka, Yasushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477528/ https://www.ncbi.nlm.nih.gov/pubmed/32149469 http://dx.doi.org/10.1111/jdi.13248

Ejemplares similares

Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus
por: Kawata, Takehiro, et al.
Publicado: (2017)

Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study
por: Iizuka, Takashi, et al.
Publicado: (2016)

Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study
por: Iizuka, Takashi, et al.
Publicado: (2016)

Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study
por: Iemitsu, Kotaro, et al.
Publicado: (2017)

Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study
por: Iemitsu, Kotaro, et al.
Publicado: (2016)

Is a Switch From Insulin Therapy to Liraglutide Possible in Japanese Type 2 Diabetes Mellitus Patients?
por: Kawata, Takehiro, et al.
Publicado: (2014)

A Study of Seasonal Variation in the Effect of Add-On Sitagliptin on Blood Glucose Control in Insulin-Treated Patients With Type 2 Diabetes
por: Takai, Masahiko, et al.
Publicado: (2020)

Pleiotropic Effects of Sitagliptin in the Treatment of Type 2 Diabetes Mellitus Patients
por: Kubota, Akira, et al.
Publicado: (2012)

Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study
por: Takai, Masahiko, et al.
Publicado: (2019)

Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study
por: Ishikawa, Masashi, et al.
Publicado: (2015)

Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
por: Kubota, Akira, et al.
Publicado: (2012)

Multinational Observational Study to Understand Insulin Treatment Intensification: Japanese Subgroup Analysis of the MOSAIc Study
por: Matsuba, Ikuro, et al.
Publicado: (2022)

Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study
por: Umezawa, Shinichi, et al.
Publicado: (2015)

Cross‐sectional survey of diabetic neuropathy in Kanagawa and clinical significance of a touch test using tissue paper
por: Jin, Yasuyuki, et al.
Publicado: (2012)

Cross-National Variation in Glycemic Control and Diabetes-Related Distress Among East Asian Patients Using Insulin: Results from the MOSAIc Study
por: Matsuba, Ikuro, et al.
Publicado: (2016)

Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes
por: Yuasa, Shouhei, et al.
Publicado: (2016)

Factors Associated With Reduced Efficacy of Sitagliptin Therapy: Analysis of 93 Patients With Type 2 Diabetes Treated for 1.5 Years or Longer
por: Kanamori, Akira, et al.
Publicado: (2013)

A survey of clinical physician's perceptions of stigma and advocacy in patients with type 2 diabetes in Kanagawa, Japan
por: Matsuzawa, Yoko, et al.
Publicado: (2022)

Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus
por: Takeda, Hiroshi, et al.
Publicado: (2019)

Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study
por: Takeda, Hiroshi, et al.
Publicado: (2016)

Present status of insulin therapy for type 2 diabetes treated by general practitioners and diabetes specialists in Japan: Third report of a cross‐sectional survey of 15,652 patients
por: Arai, Keiko, et al.
Publicado: (2012)

Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
por: Okada, Shuichi, et al.
Publicado: (2014)

Dietary survey in Japanese patients with type 2 diabetes and the influence of dietary carbohydrate on glycated hemoglobin: The Sleep and Food Registry in Kanagawa study
por: Yamakawa, Tadashi, et al.
Publicado: (2018)

The Proportion of Long-term Response to Anti-N IgG Antibody after 12 Months for COVID-19 Subclinical Infections and a Longitudinal Survey for COVID-19 Subclinical Infections in 2021
por: Matsuba, Ikuro, et al.
Publicado: (2022)

Sleep duration and food intake in people with type 2 diabetes mellitus and factors affecting confectionery intake
por: Akiyama, Tomoaki, et al.
Publicado: (2023)

Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea
por: Kubota, Akira, et al.
Publicado: (2014)

Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease
por: Kobayashi, Kazuo, et al.
Publicado: (2019)

Survey of the current status of subclinical coronavirus disease 2019 (COVID-19)
por: Matsuba, Ikuro, et al.
Publicado: (2020)

Tofogliflozin decreases body fat mass and improves peripheral insulin resistance
por: Matsuba, Ren, et al.
Publicado: (2018)

Blood pressure after treatment with sodium–glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score‐matched models
por: Kobayashi, Kazuo, et al.
Publicado: (2020)

Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
por: Morishita, Asahiro, et al.
Publicado: (2022)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021)

Study on Continuation of Antibody Prevalence Six Months after Detection of Subclinical Severe Acute Respiratory Syndrome Coronavirus 2 Infections
por: Matsuba, Ikuro, et al.
Publicado: (2021)

Effect of Caloric Intake 25 or 30 kcal/kg/day on the Glycemic Control in Obese Patients With Type 2 Diabetes
por: Masuda, Kiyomi, et al.
Publicado: (2013)

Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus
por: Kubota, Akira, et al.
Publicado: (2011)

Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial
por: Tanaka, Masashi, et al.
Publicado: (2020)

Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study
por: Ito, Daisuke, et al.
Publicado: (2017)

Ipragliflozin/tozinameran: Diabetic ketoacidosis: 2 case reports
Publicado: (2022)

Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study
por: Kishimoto, Shinji, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0mvbfac6tb94krtm68ei99pc8a